Article
Initially approved in tablet form in 2012, perampanel (Fycompa) is now available as an oral suspension.
Initially approved in tablet form in 2012, perampanel (Fycompa) is now available as an oral suspension.
Fycompa is indicated as adjunctive therapy for patients with epilepsy aged 12 years and older for the following conditions:
“The approval of Fycompa oral suspension…gives another option to patients with epilepsy who may have difficulty swallowing tablets or prefer liquids,” stated Lynn Kramer, MD, chief clinical officer and chief medical officer of Eisai’s neurology business group, in a press release.
Fycompa oral suspension will be available in 0.5 mg/mL and is expected to hit the market by summer 2016.
Pharmacist counseling points for Fycompa’s new formulation include:
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.